EUVIMEDEUVIMED entdecken
Crossref

Efficacy of Methionine Restriction and the PARP-inhibitor Olaparib and Their Combination on BRCA1 Mutant and Wild-type Triple-negative Breast Cancer Cell Lines

Mayuko Miki, Sachiko Inubushi, Qinghong Han, Shotaro Inoue, Tomonari Kunihisa, Hirokazu Tanino, Robert M Hoffman

Anticancer Research · 2025

DOI: 10.21873/anticanres.17522 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2025. Verfasst von Mayuko Miki und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Breast Surgery, Kobe University Graduate School of Medicine, Hyogo, Japan. Hauptthemen laut MEDLINE: Piperazines, Phthalazines, Triple Negative Breast Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PiperazinesPhthalazinesTriple Negative Breast NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsMethionineBRCA1 ProteinHumansCell Line, TumorFemaleMutationCell SurvivalCarbon-Sulfur LyasesDrug Resistance, NeoplasmDrug SynergismCell Proliferation

Stichwörter der Autor:innen

BRCA1 mutantDNA repairHoffman effectPARP inhibitormethionine addictionmethionine restrictionolaparibrecombinant methioninaseresistancesynergytriple-negative breast cancer (TNBC)

Substanzen

olaparibPiperazinesPhthalazinesPoly(ADP-ribose) Polymerase InhibitorsMethionineBRCA1 ProteinBRCA1 protein, humanL-methionine gamma-lyaseCarbon-Sulfur Lyases

Autor:innen und Institutionen

  • Division of Breast Surgery, Kobe University Graduate School of Medicine, Hyogo, Japan.
  • Division of Breast Surgery, Kobe University Graduate School of Medicine, Hyogo, Japan; sachiko_inubushi@people.kobe-u.ac.jp.
  • AntiCancer Inc, San Diego, CA, U.S.A.
  • Department of Cardiovascular, Respiratory and Breast Surgery, Wakayama Medical University, Wakayama, Japan.
  • AntiCancer Inc, San Diego, CA, U.S.A.; all@anticancer.com.
  • Department of Surgery, University of California San Diego, La Jolla, CA, U.S.A.

Zitieren

APA

Miki, M., Inubushi, S., Han, Q., Inoue, S., Kunihisa, T., Tanino, H., & Hoffman, R. M. (2025). Efficacy of Methionine Restriction and the PARP-inhibitor Olaparib and Their Combination on BRCA1 Mutant and Wild-type Triple-negative Breast Cancer Cell Lines. Anticancer Research. https://doi.org/10.21873/anticanres.17522

Vancouver

Miki M, Inubushi S, Han Q, Inoue S, Kunihisa T, Tanino H, et al. Efficacy of Methionine Restriction and the PARP-inhibitor Olaparib and Their Combination on BRCA1 Mutant and Wild-type Triple-negative Breast Cancer Cell Lines. Anticancer Research. 2025. doi:10.21873/anticanres.17522

BibTeX
@article{Miki2025,
  author = {Miki, Mayuko and Inubushi, Sachiko and Han, Qinghong and Inoue, Shotaro and Kunihisa, Tomonari and Tanino, Hirokazu and Hoffman, Robert M},
  title = {Efficacy of Methionine Restriction and the PARP-inhibitor Olaparib and Their Combination on BRCA1 Mutant and Wild-type Triple-negative Breast Cancer Cell Lines},
  journal = {Anticancer Research},
  year = {2025},
  doi = {10.21873/anticanres.17522}
}
Kostenlos starten →